Peptides Defined
Shop

Maintenance evidence

What Happens When You Stop GLP-1 Drugs? Weight Regain, Maintenance, and the Evidence

A research-literacy guide to GLP-1 withdrawal and maintenance evidence from semaglutide STEP trials, tirzepatide SURMOUNT-4, and newer weight-regain analyses.

By
PD Team
Published
May 26, 2026
Last updated
May 26, 2026
Read time
12 min read
Citations
12 citations
Review
Editorially reviewed by PD Team
Three unlabeled peptide vials with abstract incretin receptor and molecular graphics.

One of the most common GLP-1 questions is also one of the easiest to oversimplify: what happens when someone stops treatment? The short answer from semaglutide and tirzepatide trials is that weight regain is common after withdrawal, but the details depend on the drug, trial design, prior weight loss, follow-up period, and what other support continued after treatment stopped.

This is not a dosing guide or a recommendation to start, stop, restart, or continue any medication. It is an evidence-literacy article for interpreting trial results, product labels, and online claims about "coming off" GLP-1 drugs.

Bottom Line

In controlled trials, stopping GLP-1 or incretin-based obesity pharmacotherapy often led to partial weight regain. In the STEP 1 extension, participants regained about two-thirds of prior semaglutide-associated weight loss during the year after withdrawal. In SURMOUNT-4, participants who switched from tirzepatide to placebo regained substantial weight, while those who continued tirzepatide maintained and added to prior weight reduction.

That pattern does not mean the medicines "only work while you take them" in a dismissive sense. It means obesity pharmacotherapy is being studied and labeled in a chronic-disease context. Many long-term medicines work while the treatment pressure is present, and disease markers can worsen when treatment is withdrawn.

The practical reading is sober: trials support the idea that maintenance matters. They do not prove that every person needs the same maintenance plan, dose, duration, or medication.

Why Weight Regain Can Happen After Stopping

GLP-1 receptor agonists and dual incretin agonists affect appetite, food intake, glucose regulation, gastric emptying, and body-weight physiology. When that pharmacologic effect is removed, the body is no longer receiving the same appetite and metabolic signal. Weight-regain risk then depends on energy intake, energy expenditure, adaptive physiology, behavior, comorbidities, background care, and time.

It is useful to compare this with hypertension or hyperlipidemia. If blood pressure rises after an antihypertensive is stopped, that does not prove the antihypertensive was fake. It shows that the underlying condition can reassert itself when treatment is removed.

Obesity trials increasingly use that chronic-treatment framing. The key question is no longer just "how much weight can be lost by week 68?" It is also "what happens during continued therapy, withdrawal, maintenance, or transition?"

Trial Evidence Snapshot

Study Drug Design context Maintenance takeaway
STEP 1 extension Semaglutide 2.4 mg Participants stopped semaglutide and lifestyle intervention after the 68-week STEP 1 trial and were followed for 52 additional weeks. Participants regained about two-thirds of prior weight loss after withdrawal, and cardiometabolic improvements moved back toward baseline.
STEP 4 Semaglutide 2.4 mg After a 20-week semaglutide run-in, participants either continued semaglutide or switched to placebo for 48 weeks. Continuing semaglutide supported further weight reduction, while switching to placebo was associated with regain.
STEP 5 Semaglutide 2.4 mg Two-year randomized trial of semaglutide 2.4 mg plus lifestyle intervention in adults with overweight or obesity. Longer continued treatment sustained substantial mean weight loss over 104 weeks in the studied population.
SURMOUNT-4 Tirzepatide After a 36-week open-label tirzepatide lead-in, participants either continued tirzepatide or switched to placebo for 52 weeks. Participants who continued tirzepatide maintained and augmented weight reduction; those switched to placebo regained substantial weight.

What Semaglutide Trials Show

The STEP 1 extension is the clearest withdrawal example for semaglutide 2.4 mg. After the 68-week trial period, participants stopped semaglutide and lifestyle intervention. During the following year, the extension reported substantial weight regain and reversal of cardiometabolic improvements toward baseline.

STEP 4 asked a different maintenance question. Participants first received semaglutide during a run-in period, then were randomized either to continue semaglutide or switch to placebo. Those who continued semaglutide had better weight-maintenance outcomes than those who switched to placebo.

STEP 5 adds the long-duration perspective. In that two-year trial, continued semaglutide plus lifestyle intervention sustained substantial average weight reduction over 104 weeks. Together, STEP 1 extension, STEP 4, and STEP 5 support the same broad point: withdrawal and continued treatment are not equivalent conditions.

What Tirzepatide Trials Show

SURMOUNT-4 is the key tirzepatide maintenance-withdrawal trial. Participants first received open-label tirzepatide for 36 weeks. Those who tolerated and stayed in the trial were then randomized to continue tirzepatide or switch to placebo for 52 weeks.

The continuation group maintained and extended weight reduction. The placebo-switch group regained substantial weight. This design is important: the trial did not ask whether tirzepatide starts weight loss from baseline. It asked what happens after a treatment response when the drug is continued or withdrawn.

That distinction matters for online claims. SURMOUNT-4 is evidence for maintenance dynamics after prior tirzepatide exposure, not a universal prediction of what will happen to every person who stops.

Maintenance Is Not One Thing

"Maintenance" can mean continued medication, lower-intensity lifestyle support, a different medication, a different dose strategy, nutrition and resistance-training emphasis, monitoring, or a combination of approaches. The trial evidence tells us withdrawal often increases regain risk. It does not prescribe a single maintenance plan for all patients.

The other point is that weight is not the only endpoint. For people using GLP-1 or incretin-based medications for type 2 diabetes, cardiovascular risk, kidney risk, sleep apnea, or other labeled conditions, stopping therapy may have implications beyond body weight. Those decisions require clinical context.

Peptides Defined covers this as research literacy. Readers should not turn a maintenance trial into self-directed medication changes, and they should not treat unapproved products sold online as equivalent to FDA-reviewed products used in the trials.

How To Check Online Claims About Stopping

Common claim Better interpretation
If weight returns after stopping, the drug did not work. That is not how chronic-disease pharmacology is usually interpreted. Blood pressure, lipids, glucose, and body weight can all worsen after a working treatment is withdrawn.
Everyone regains all the weight immediately. Trials report group averages over defined follow-up periods. Individual outcomes vary by biology, dose exposure, lifestyle support, tolerability, concurrent therapy, and follow-up duration.
Maintenance always means staying on the same drug forever. Maintenance is a clinical strategy question, not a one-size rule. Trials show withdrawal risk, but individual decisions belong with licensed clinicians.
Regain means GLP-1s are just cosmetic. That framing ignores type 2 diabetes, cardiovascular, kidney, sleep-apnea, and obesity trial endpoints. It also ignores that obesity is commonly treated as a chronic relapsing condition.

The most useful next question is always specific: Which drug? Which dose range? Which trial? How long after withdrawal? Was lifestyle support continued? Was the product approved, compounded, or investigational? Were outcomes based on measured trial endpoints or anecdote?

References